Professor; Head of Medical Division, Turku university Hospital Ilkka Kantola - UTU Research Portal

Ilkka Kantola
Professor; Head of Medical Division, Turku university Hospital

- Docent,
Faculty of Medicine (University of Turku)

ilkkan@utu.fi

: https://orcid.org/0000-0002-6228-522X

CURRICULUM VITAE OF ILKKA KANTOLA041117.pdf

Hypertensio;Fabry disease; diabetes mellitus; sleep apnea

2 of 5

Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene (2020)
- Heart
Valtola Kati, Nino-Quintero Juanita, Hedman Marja, Lottonen-Raikaslehto Line, Laitinen Tomi, Maria Maleeha, Kantola Ilkka, Naukkarinen Anita, Laakso Markku, Kuusisto Johanna
Kohonnut verenpaine – Käypä hoito -suositus (2020) Kohonnut verenpaine – Käypä hoito -suositus Antti Jula, Ilkka Kantola, Päivi Korhonen, Seppo Lehto, Eero Mervaala, Kaj Metsärinne, Teemu Niiranen, Ilkka Pörsti, Timo Strandberg, Mikko Syvänne, Ilkka Tikkanen
Kohonnut verenpaine – Käypä hoito -suositus päivitystiivistelmä (2020)
- Duodecim
Antti Jula, Ilkka Kantola, Päivi Korhonen, Seppo Lehto, Eero Mervaala, Kaj Metsärinne, Teemu Niiranen, Ilkka Pörsti, Timo Strandberg, Mikko Syvänne, Ilkka Tikkanen
Self-monitoring of blood pressure in patients with hypertension related multi-morbidity: Systematic review and individual patient data meta-analysis (2020)
- American Journal of Hypertension
Sheppard JP, Tucker KL, Davison WJ, Stevens R, Aekplakorn W, Bosworth HB, Bove A, Earle K, Godwin M, Green BB, Hebert P, Heneghan C, Hill N, Hobbs FDR, Kantola I, Leiva A, Kerry SM, Mant J, Magid DJ, McKinstry B, Margolis KL, McNamara K, McLaughlin MA, Ogedegbe O, Omboni S, Varis J, Parati G, Wakefield BJ, Verberk WJ, McManus RJ
STONE HF -tutkimuksen viesti lääkäreille: suojaa tyypin 2 diabeetikon sydäntä ja munuaisia (2020)
- Diabetes ja lääkäri
Metsärinne Kaj, Kantola Ilkka, Niskanen Leo, Pietilä Mikko, Poussa Tuija, Stenman Lotta
Unsupervised hierarchical clustering identifies a metabolically challenged subgroup of hypertensive individuals (2020)
- Journal of Clinical Hypertension
Felix C. Vaura, Veikko V. Salomaa, Ilkka M. Kantola, Risto Kaaja, Leo Lahti, Teemu J. Niiranen
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019)
- Lancet
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; on behalf of the SONAR Committees and Investigators
Fabry-kardiomyopatia (2019)
- Sydänääni: Suomen Kardiologisen Seuran Lehti
Ilkka Kantola, Johanna Kuusisto
Home and office blood pressure measurements as determinants of kidney disease in the general population: The Finn-Home Study (2019)
- European Journal of Preventive Cardiology
Sam SE Sivén, Ville L Langén, Pauli Puukka, Jouko Sundvall, Ilkka M Kantola, Antti M Jula, Teemu J Niiranen
Natural course of Fabry disease with the p Arg227Ter (pR227*) mutation in Finland: Fast study (2019)
- Molecular Genetics and Genomic Medicine
Pietilä-Effati P, Saarinen JT, Löyttyniemi E, Autio R, Saarenhovi M, Haanpää MK, Kantola I
Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data (2019)
- Clinical Pharmacology and Therapeutics
Simon Körver, Ulla Feldt‐Rasmussen, Einar Svarstad, Ilkka Kantola, Mirjam Langeveld
Renal involvement in Fabry disease (2019)
- Nephrology Dialysis Transplantation
Ilkka M Kantola
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts (2019)
- Molecular Genetics and Metabolism Reports
Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M
European expert consensus statement on therapeutic goals in Fabry disease (2018)
- Molecular Genetics and Metabolism
Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymanska A, Tondel C, Viana-Baptista M, Weidemann F, Hilz MJ, Hilz MJ
Fabryn tauti, harvinainen lysosomaalinen kertymäsairaus (2018)
- Erikoislääkäri
Kantola I
Ortostaattisen hypotension tutkiminen ja hoito (2018)
- Lääkärilehti
Ilkka Kantola, Antti Jula, Teemu Niiranen
Relation of blood pressure and organ damage: comparison between feasible, noninvasive central hemodynamic measures and conventional brachial measures (2018)
- Journal of Hypertension
Lindroos AS, Langen VL, Kantola I, Salomaa V, Juhanoja EP, Siven SS, Jousilahti P, Jula AM, Niiranen TJ
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial (2018)
- Lancet
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators
Verenpainetaudin, sepelvaltimotaudin ja sydämen vajaatoiminnan lääkehoito (2018) Farmakologia ja toksikologia Kantola I., Mervaala E.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients (2017)
- New England Journal of Medicine
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.